Abstract 1411P
Background
Gastric cancer is a malignant tumor with high incidence and high mortality. Apatinib (a highly selective TKI against VEGFR-2) showed promising effificacy in the treatment of advanced or metastatic gastric cancer in phase II and III studies. The aim of this study was to observe and evaluate the efficacy and safety of apatinib for the treatment of gastric cancer in real word clinical practice.
Methods
The eligible patients with gastric cancer, who received any treatment based on apatinib, were enrolled. The primary endpoint were major pathologic response (MPR), disease-free survival (DFS), and progression-free survival (PFS). The secondary endpoints were overall survival (OS), overall response rate (ORR), disease control rate (DCR), and adverse events (AE).
Results
These were the results of periodic analysis. A total of 257 patients were included between September 28, 2020, and December 31, 2020. Most patients were male (n=171, 66.54%), with a median age of 62 (range 28-83) years and had an ECOG PS of 0 (n=39, 15.18%) or 1 (n=203, 78.99%). The treatment of apatinib was mainly first-line treatment (n=103, 40.08%), second-line treatment (n=64, 24.90%), and adjuvant treatment (n=42, 16.34%). The starting dose of apatinib was 250mg in 132 patients and 500mg in 125 patients. The treatment regimens were: apatinib combined with chemotherapy drugs (178/257), apatinib monotherapy (64/257), apatinib combined with chemotherapy drugs plus PD- 1 antibody drug (8/275), and apatinib combined with PD- 1 antibody drug (7/275). Thirty-three patients achieved partial response, 69 patients achieved stable disease, and 26 patients had progressive disease, and no CR was achieved, illustrating an ORR of 25.78% and a DCR of 79.69%. During the treatment, the overall incidence of adverse events was 70.82%. The most common adverse events were hypertension (32.68%), leukopenia (26.46%), hand-foot syndrome (25.29%), neutropenia (20.23%), etc.
Conclusions
This real-world research showed current treatment status and provided preliminary evidence for the efficacy and safety of apatinib in the treatment of gastric cancer in China. More data would be analyzed and reported in future. [ChiCTR2000035597]
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.